Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 6, 2018
Issued Date -
N/A
app pub date -
Oct 21, 2016
filing date -
Sep 14, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully